[18F]AlF-NOTA-JR11的合成、临床前评价及与[68Ga]Ga-DOTA-TATE对比的神经内分泌肿瘤初步临床显像研究
研究开发了[18F]AlF标记的生长抑素受体拮抗剂[18F]AlF-NOTA-JR11,在细胞和荷瘤小鼠中评价并与[68Ga]Ga-DOTA-TATE对比,并在10例神经内分泌肿瘤患者中行PET/MR与PET/CT显像;结果显示[18F]AlF-NOTA-JR11标记便捷、亲和力高,患者中仅其检出的病灶数更多(67 vs 1),多数正常器官摄取更低,肝病灶SUVmax靶/非靶比更高。
要点
- [18F]AlF-NOTA-JR11制备便捷,放化产率51.35±3.30%,放化纯度98.74±1.24%。
- 患者中仅[18F]AlF-NOTA-JR11检出病灶67个,仅[68Ga]Ga-DOTA-TATE检出1个。
- [18F]AlF-NOTA-JR11多数正常器官摄取显著低于[68Ga]Ga-DOTA-TATE。
核心结论
- 合格[18F]AlF-NOTA-JR11制备便捷、产率合理,可高亲和力特异性结合SSTR2。
- [18F]AlF-NOTA-JR11对NEN显像能力优于[68Ga]Ga-DOTA-TATE,尤其在消化系统。
研究设计与样本
- 研究包括手动合成与HPLC/LC-MS质控、HEK293-SSTR2细胞摄取/内化/饱和结合实验、荷瘤小鼠生物分布与micro-PET成像。
- 临床部分对10例NEN患者行[18F]AlF-NOTA-JR11 PET/MR和[68Ga]Ga-DOTA-TATE PET/CT,注射后50~60 min采集。
主要发现
- [18F]AlF-NOTA-JR11放化产率51.35±3.30%(n>10),放化纯度98.74±1.24%(n>10),制备在30 min内完成。
- 发现两种立体异构体并经LC-MS确认。
- 30 min细胞摄取两者均为4.50 %AD/10^5 cells([18F]AlF-NOTA-JR11 4.50±0.31,[68Ga]Ga-DOTA-TATE 4.50±0.13)。
- 37℃ 60 min内化[18F]AlF-NOTA-JR11为5.47±0.32%,显著低于[68Ga]Ga-DOTA-TATE的66.89±1.62%。
- 亲和力[18F]AlF-NOTA-JR11 Kd=11.59±1.31 nM,略低于[68Ga]Ga-DOTA-TATE Kd=7.36±1.02 nM。
关键数值与推荐
- 荷瘤小鼠60 min肿瘤摄取[18F]AlF-NOTA-JR11为9.02±0.92 %ID/g,可被50 μg NOTA-JR11阻断至3.40±1.64 %ID/g。
- 患者中仅[18F]AlF-NOTA-JR11检出病灶67个,仅[68Ga]Ga-DOTA-TATE检出1个。
- 肝病灶[18F]AlF-NOTA-JR11的SUVmax靶/非靶比显著高于[68Ga]Ga-DOTA-TATE。
临床怎么用
- [18F]AlF-NOTA-JR11可用于NEN的SSTR2靶向PET显像,尤其消化系统病灶检出可能更优。
- 其多数正常器官摄取较低,可能有利于病灶对比度提升。
局限性
- 临床影像仅纳入10例NEN患者,样本量有限。
- 为初步临床成像研究,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A [18F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [68Ga]Ga-DOTA-TATE. METHOD: [18F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). The cellular uptake, internalization, and saturation binding were performed with HEK293-SSTR2 cells. Biodistribution and micro-PET imaging were carried out with HEK293-SSTR2 tumor-bearing mice. [18F]AlF-NOTA-JR11 PET/MR imaging and [68Ga]Ga-DOTA-TATE PET/CT were performed with ten patients of NEN at 50~60 min post-injection (p.i.). Normal organ biodistribution and tumor detectability were evaluated. RESULT: [18F]AlF-NOTA-JR11(24~36 GBq/μmol) was prepared within 30 min and 51.35 ± 3.30% (n > 10)of radiochemical yield. The radiochemical purity was 98.74 ± 1.24% (n > 10). Two stereoisomers were found and confirmed by LC-MS. The cellular uptake of [18F]AlF-NOTA-JR11 and [68Ga]Ga-DOTA-TATE were 4.50 ± 0.31 and 4.50 ± 0.13 %AD/105 cells at 30 min, and the internalization at 37 °C of [18F]AlF-NOTA-JR11 (5.47 ± 0.32% at 60 min) was significantly lower than [68Ga]Ga-DOTA-TATE (66.89 ± 1.62% at 60 min). The affinity of [18F]AlF-NOTA-JR11 (Kd = 11.59 ± 1.31 nM) was slightly lower than [68Ga]Ga-DOTA-TATE (Kd = 7.36 ± 1.02 nM); [18F]AlF-NOTA-JR11 showed high uptake in tumor (9.02 ± 0.92 %ID/g at 60 min p.i.) which can be blocked by 50 μg of NOTA-JR11 (3.40 ± 1.64 %ID/g at 60 min p.i.); the result was coincident with micro-PET imaging. Imaging study of NEN patients showed that more lesions were found only by [18F]AlF-NOTA-JR11 (n = 67 vs. 1 only by [68Ga]Ga-DOTA-TATE), and the uptakes of [18F]AlF-NOTA-JR11 in majority normal organs were significantly lower than [68Ga]Ga-DOTA-TATE. The target to nontarget of maximum of standard uptake value (SUVmax) of [18F]AlF-NOTA-JR11 in liver lesions were significantly higher than those of [68Ga]Ga-DOTA-TATE. CONCLUSION: Qualitied [18F]AlF-NOTA-JR11 is prepared conveniently with reasonable yield, and it can bind SSTR2 specifically with high affinity. Excellent imaging capability of [18F]AlF-NOTA-JR11 for NENs is superior to [68Ga]Ga-DOTA-TATE, especially in digestive system. It has a great potential for imaging of NENs.
引用
- Xie Q, Liu T, Ding J, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021. PMID: 33630145. doi:10.1007/s00259-021-05249-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。